balance sheet strength

Leatt Corporation reported 41% revenue growth to $61.9M and 248% net income surge to $3.26M in 2025, marking its sixth consecutive quarterly growth with strength across all product categories.

Four financial services firms offer attractive dual returns through dividends and buybacks, supported by strong free cash flow and solid balance sheets.

The Trade Desk shares crashed 74% from highs amid Publicis dispute, yet strong fundamentals including $2.9B revenue and $440M net income suggest overvaluation.

BP sells German refinery to Klesch Group and raises structural cost targets to $7.5 billion by 2027, signaling aggressive transformation amid energy sector shifts.

Costco sees institutional buying surge as strong Q2 earnings, $17.3B cash hoard, and 4-to-1 buy-sell ratio signal fresh all-time highs ahead.

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.

Healthcare REITs show divergent economic resilience: Welltower's $145B scale and 3.0x leverage outperform Medical Properties Trust's riskier 8.5x ratio during downturns.

Institutional investors favor high-growth companies with strong balance sheets, like NVIDIA and Eli Lilly, viewing them as resilient bets in volatile markets.

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.

Colliers extends revolving credit facility to 2031 with $2.25B commitment and adds $250M accordion feature to support growth and acquisition strategy.

Equinox Gold launches shareholder returns program with inaugural quarterly dividend of $0.015 per share and 5% share buyback authorization, reflecting improved financial strength.

Barington Companies buys $5.56M stake in Chemed as stock drops 15% YoY, viewing depressed valuation as opportunity in healthcare-services company.